Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Jun;71(6):4339–4346. doi: 10.1128/jvi.71.6.4339-4346.1997

Retention of viral infectivity after extensive mutation of the highly conserved immunodominant domain of the feline immunodeficiency virus envelope.

G Pancino 1, P Sonigo 1
PMCID: PMC191650  PMID: 9151822

Abstract

In lentiviruses, including human immunodeficiency virus and feline immunodeficiency virus (FIV), the principal immunodominant domain (PID) of the transmembrane glycoprotein elicits a strong humoral response in infected hosts. The PID is marked by the presence of two cysteines that delimit a sequence, composed of five to seven amino acids in different lentiviruses, which is highly conserved among isolates of the same lentiviral species. While the conservation of the sequence suggests the presence of functional constraints, the conservation of the immunodominance among divergent lentiviruses raises the hypothesis of a selective advantage for the infecting virus conferred by the host humoral response against this domain. We and others have previously shown that an appropriate structure of the PID is required for the production of a functional envelope. In the present work, we analyzed virological functions and immune reactivity of the envelope after random mutagenesis of the PID of FIV. We obtained nine mutant envelopes which were correctly processed and retained fusogenic ability. Mutation of the two C-terminal residues of the PID sequence between the cysteines in a molecular clone of FIV abolished infectivity. In contrast, three molecular clones containing extensive mutations in the four N-terminal amino acids were infectious. However, the mutations affected PID reactivity with sera from infected cats. Our results suggest that functional constraints, although existent, are not sufficient to account for PID sequence conservation. Such conservation may also result from positive selection by anti-PID antibodies which enhance infection.

Full Text

The Full Text of this article is available as a PDF (1.4 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avrameas A., Strosberg A. D., Moraillon A., Sonigo P., Pancino G. Serological diagnosis of feline immunodeficiency virus infection based on synthetic peptides from Env glycoproteins. Res Virol. 1993 May-Jun;144(3):209–218. doi: 10.1016/s0923-2516(06)80031-2. [DOI] [PubMed] [Google Scholar]
  2. Bertoni G., Zahno M. L., Zanoni R., Vogt H. R., Peterhans E., Ruff G., Cheevers W. P., Sonigo P., Pancino G. Antibody reactivity to the immunodominant epitopes of the caprine arthritis-encephalitis virus gp38 transmembrane protein associates with the development of arthritis. J Virol. 1994 Nov;68(11):7139–7147. doi: 10.1128/jvi.68.11.7139-7147.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cao J., Bergeron L., Helseth E., Thali M., Repke H., Sodroski J. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol. 1993 May;67(5):2747–2755. doi: 10.1128/jvi.67.5.2747-2755.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chong Y. H., Ball J. M., Issel C. J., Montelaro R. C., Rushlow K. E. Analysis of equine humoral immune responses to the transmembrane envelope glycoprotein (gp45) of equine infectious anemia virus. J Virol. 1991 Feb;65(2):1013–1018. doi: 10.1128/jvi.65.2.1013-1018.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dedera D., Gu R. L., Ratner L. Conserved cysteine residues in the human immunodeficiency virus type 1 transmembrane envelope protein are essential for precursor envelope cleavage. J Virol. 1992 Feb;66(2):1207–1209. doi: 10.1128/jvi.66.2.1207-1209.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dubay J. W., Roberts S. J., Hahn B. H., Hunter E. Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol. 1992 Nov;66(11):6616–6625. doi: 10.1128/jvi.66.11.6616-6625.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eaton A. M., Ugen K. E., Weiner D. B., Wildes T., Levy J. A. An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Res Hum Retroviruses. 1994 Jan;10(1):13–18. doi: 10.1089/aid.1994.10.13. [DOI] [PubMed] [Google Scholar]
  8. Fontenot J. D., Hoover E. A., Elder J. H., Montelaro R. C. Evaluation of feline immunodeficiency virus and feline leukemia virus transmembrane peptides for serological diagnosis. J Clin Microbiol. 1992 Jul;30(7):1885–1890. doi: 10.1128/jcm.30.7.1885-1890.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gallaher W. R., Ball J. M., Garry R. F., Griffin M. C., Montelaro R. C. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses. 1989 Aug;5(4):431–440. doi: 10.1089/aid.1989.5.431. [DOI] [PubMed] [Google Scholar]
  10. Gnann J. W., Jr, McCormick J. B., Mitchell S., Nelson J. A., Oldstone M. B. Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science. 1987 Sep 11;237(4820):1346–1349. doi: 10.1126/science.2888192. [DOI] [PubMed] [Google Scholar]
  11. Goff S., Traktman P., Baltimore D. Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. J Virol. 1981 Apr;38(1):239–248. doi: 10.1128/jvi.38.1.239-248.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Heath S. L., Tew J. G., Tew J. G., Szakal A. K., Burton G. F. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature. 1995 Oct 26;377(6551):740–744. doi: 10.1038/377740a0. [DOI] [PubMed] [Google Scholar]
  13. Hunter E., Swanstrom R. Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol. 1990;157:187–253. doi: 10.1007/978-3-642-75218-6_7. [DOI] [PubMed] [Google Scholar]
  14. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  15. Mascola J. R., Mathieson B. J., Zack P. M., Walker M. C., Halstead S. B., Burke D. S. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses. 1993 Dec;9(12):1175–1184. doi: 10.1089/aid.1993.9.1175. [DOI] [PubMed] [Google Scholar]
  16. Moraillon A., Barré-Sinoussi F., Parodi A., Moraillon R., Dauguet C. In vitro properties and experimental pathogenic effect of three strains of feline immunodeficiency viruses (FIV) isolated from cats with terminal disease. Vet Microbiol. 1992 Apr;31(1):41–54. doi: 10.1016/0378-1135(92)90140-O. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Norrby E., Biberfeld G., Chiodi F., von Gegerfeldt A., Nauclér A., Parks E., Lerner R. Discrimination between antibodies to HIV and to related retroviruses using site-directed serology. Nature. 1987 Sep 17;329(6136):248–250. doi: 10.1038/329248a0. [DOI] [PubMed] [Google Scholar]
  18. Norrby E., Biberfeld G., Johnson P. R., Parks D. E., Houghten R. A., Lerner R. A. The chemistry of site-directed serology for HIV infections. AIDS Res Hum Retroviruses. 1989 Oct;5(5):487–493. doi: 10.1089/aid.1989.5.487. [DOI] [PubMed] [Google Scholar]
  19. Oldstone M. B., Tishon A., Lewicki H., Dyson H. J., Feher V. A., Assa-Munt N., Wright P. E. Mapping the anatomy of the immunodominant domain of the human immunodeficiency virus gp41 transmembrane protein: peptide conformation analysis using monoclonal antibodies and proton nuclear magnetic resonance spectroscopy. J Virol. 1991 Apr;65(4):1727–1734. doi: 10.1128/jvi.65.4.1727-1734.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Osborne R., Rigby M., Siebelink K., Neil J. C., Jarrett O. Virus neutralization reveals antigenic variation among feline immunodeficiency virus isolates. J Gen Virol. 1994 Dec;75(Pt 12):3641–3645. doi: 10.1099/0022-1317-75-12-3641. [DOI] [PubMed] [Google Scholar]
  21. Pancino G., Camoin L., Sonigo P. Structural analysis of the principal immunodominant domain of the feline immunodeficiency virus transmembrane glycoprotein. J Virol. 1995 Apr;69(4):2110–2118. doi: 10.1128/jvi.69.4.2110-2118.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pancino G., Castelot S., Sonigo P. Differences in feline immunodeficiency virus host cell range correlate with envelope fusogenic properties. Virology. 1995 Feb 1;206(2):796–806. doi: 10.1006/viro.1995.1002. [DOI] [PubMed] [Google Scholar]
  23. Pancino G., Chappey C., Saurin W., Sonigo P. B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins. J Virol. 1993 Feb;67(2):664–672. doi: 10.1128/jvi.67.2.664-672.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Robinson W. E., Jr, Gorny M. K., Xu J. Y., Mitchell W. M., Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol. 1991 Aug;65(8):4169–4176. doi: 10.1128/jvi.65.8.4169-4176.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Robinson W. E., Jr, Kawamura T., Lake D., Masuho Y., Mitchell W. M., Hersh E. M. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol. 1990 Nov;64(11):5301–5305. doi: 10.1128/jvi.64.11.5301-5305.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sattentau Q. J., Moore J. P. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med. 1991 Aug 1;174(2):407–415. doi: 10.1084/jem.174.2.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sattentau Q. J., Zolla-Pazner S., Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology. 1995 Jan 10;206(1):713–717. doi: 10.1016/s0042-6822(95)80094-8. [DOI] [PubMed] [Google Scholar]
  28. Schulz T. F., Jameson B. A., Lopalco L., Siccardi A. G., Weiss R. A., Moore J. P. Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins? AIDS Res Hum Retroviruses. 1992 Sep;8(9):1571–1580. doi: 10.1089/aid.1992.8.1571. [DOI] [PubMed] [Google Scholar]
  29. Sibille P., Avraméas A., Moraillon A., Richardson J., Sonigo P., Pancino G., Strosberg A. D. Comparison of serological tests for the diagnosis of feline immunodeficiency virus infection of cats. Vet Microbiol. 1995 Jul;45(2-3):259–267. doi: 10.1016/0378-1135(94)00128-j. [DOI] [PubMed] [Google Scholar]
  30. Syu W. J., Lee W. R., Du B., Yu Q. C., Essex M., Lee T. H. Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity. J Virol. 1991 Nov;65(11):6349–6352. doi: 10.1128/jvi.65.11.6349-6352.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Talbott R. L., Sparger E. E., Lovelace K. M., Fitch W. M., Pedersen N. C., Luciw P. A., Elder J. H. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5743–5747. doi: 10.1073/pnas.86.15.5743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Unger R. E., Marthas M. L., Lackner A. A., Pratt-Lowe E., Lohman B. L., Van Rompay K., Luciw P. A. Detection of simian immunodeficiency virus DNA in macrophages from infected rhesus macaques. J Med Primatol. 1992 Feb-May;21(2-3):74–81. [PubMed] [Google Scholar]
  33. Zhang H., Zhang Y., Spicer T., Henrard D., Poiesz B. J. Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle. J Virol. 1995 Jun;69(6):3675–3682. doi: 10.1128/jvi.69.6.3675-3682.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES